Pharma-Bio Serv Announces Full Year Results -January 30, 2024 at 0808 am EST - Marketscreener.com
| PBSV Stock | USD 0.55 0.06 9.84% |
Slightly above 61% of Pharma Bio's investor base is looking to short. The analysis of current outlook of investing in Pharma Bio Serv suggests that many traders are alarmed regarding Pharma Bio's prospects. Pharma Bio's investing sentiment can be driven by a variety of factors including economic data, Pharma Bio's earnings reports, geopolitical events, and overall market trends.
Pharma Bio otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Pharma daily returns and investor perception about the current price of Pharma Bio Serv as well as its diversification or hedging effects on your existing portfolios.
Pharma |
Pharma-Bio Serv Announces Full Year Results -January 30, 2024 at 0808 am EST Marketscreener.com
Read at news.google.com
 |
Pharma Bio Fundamental Analysis
We analyze Pharma Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Bio based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Z Score
Z Score Comparative Analysis
Pharma Bio is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Pharma Bio Serv Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharma Bio otc stock to make a market-neutral strategy. Peer analysis of Pharma Bio could also be used in its relative valuation, which is a method of valuing Pharma Bio by comparing valuation metrics with similar companies.
Peers
Pharma Bio Related Equities
| OPRX | OPTIMIZERx Corp | 6.61 | ||||
| CCLD | CareCloud | 5.23 | ||||
| VHIBF | Vitalhub Corp | 3.11 | ||||
| CERT | Certara | 0.87 | ||||
| HSTM | HealthStream | 0.52 | ||||
| DH | Definitive Healthcare | 0.67 | ||||
| OMCL | Omnicell | 1.50 | ||||
| HCTI | Healthcare Triangle | 3.23 | ||||
| NRC | National Research | 3.37 | ||||
| EUDA | EUDA Health | 7.38 | ||||
| ACON | Aclarion | 8.33 |
Additional Tools for Pharma OTC Stock Analysis
When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.